Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies (Q33234057)

24 July 2017

Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies (English)

1 reference

24 July 2017

1 reference

Juqun Shen

1

1 reference

24 July 2017

Marie Danielle Vil

2

1 reference

24 July 2017

Xenia Jimenez

3

1 reference

24 July 2017

Michelle Iacolina

4

1 reference

24 July 2017

Haifan Zhang

5

1 reference

24 July 2017

Zhenping Zhu

6

1 reference

24 July 2017

language of work or name

English

0 references

publication date

15 February 2006

1 reference

Journal of Biological Chemistry

24 July 2017

1 reference

24 July 2017

281

1 reference

24 July 2017

16

1 reference

24 July 2017

10706-10714

1 reference

Recombinant bispecific antibodies for cancer therapy

24 July 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Augmentation of antitumor effects of p53 gene therapy by combination with HDAC inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Toward the production of bispecific antibody fragments for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Bispecific human IgG by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Recombinant approaches to IgG-like bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

An efficient route to human bispecific IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Design and production of novel tetravalent bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

A melanoma-specific VH antibody cloned from a fusion phage library of a vaccinated melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Optimal design features of camelized human single-domain antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins".

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Crystal structure of a shark single-domain antibody V region in complex with lysozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Domain antibodies: proteins for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Engineered proteins as specific binding reagents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

Hybrid hybridomas and their use in immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M513415200

21 January 2018

Identifiers

DOI

10.1074/JBC.M513415200

1 reference

24 July 2017

1 reference